Updated:
PierianDx
PierianDx is a St. Louis-based company founded in 2014. It provides technology for clinical labs to offer patient-specific diagnoses and treatments.
PierianDx
PierianDx is a St. Louis-based company founded in 2014. It provides technology for clinical labs to offer patient-specific diagnoses and treatments. The company has secured $62 million in total funding.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Salt Lake City
Corporate office
Salt Lake City, UT, United States
Sector focus
Frequently asked questions
Does PierianDx manage capital for external allocators?
No. PierianDx is a clinical-genomics software and services company, not a fund manager or family office. It has raised venture capital and debt from outside investors but does not deploy third-party capital into other companies or assets.
How does PierianDx's platform differ from consumer genomics tools?
PierianDx focuses on clinical-grade interpretation for diagnostic use, meaning results are validated for use in treatment decision-making by physicians. Unlike 23andMe or similar consumer services, PierianDx's platform complies with CLIA and CAP laboratory standards and integrates into hospital electronic health records for oncology workflows.
What investment stages does PierianDx typically target?
PierianDx does not make external investments. The company itself has raised venture capital at the Series B stage (2018) and subsequent venture debt rounds. It operates as a growth-stage healthcare technology company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: